Form 4: Medpace Holdings CEO August J. Troendle Sells $82 Million in Shares

Medpace Holdings CEO August J. Troendle sold 200,000 shares of common stock over three days in March 2024, through Medpace Investors, LLC.

Summary

• August J. Troendle, CEO of Medpace Holdings, Inc., sold 200,000 shares of common stock between March 6 and March 8, 2024.
• The sales were executed through Medpace Investors, LLC (MPI), where Troendle serves as the sole manager and controlling unit holder.
• The transactions were carried out pursuant to a limit order placed by MPI during an open window period.
• The sales occurred in multiple transactions at weighted average prices of $412.98, $410.74, and $408.71 on March 6, 7, and 8, respectively.
• Following these transactions, Troendle indirectly beneficially owns 4,733,019 shares through MPI, and directly owns 806,643 shares.

Sentiment

Score: 5

Explanation: The document itself is neutral, simply reporting the facts of the stock sale. The sentiment is slightly negative as insider selling can sometimes be perceived as a lack of confidence in the company's future prospects, but it's also a routine event.

Management Comments

• The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.
• The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Industry Context

Insider sales are a common occurrence, but large sales by CEOs can sometimes be interpreted negatively by the market, depending on the context and the company's performance.

Stakeholder Impact

• Shareholders may react to the news of the CEO's stock sale, potentially impacting the stock price.

Key Dates